The role and molecular mechanism of IgG4 driving adipose tissue macrophage polarization targeting lipid metabolism in thyroid-associated ophthalmopathy diseases

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400094162

Enrollment

Unknown

Registered

2024-12-17

Start date

2025-01-01

Completion date

Unknown

Last updated

2025-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thyroid-associated ophthalmopathy, TAO

Interventions

TAO, IgG4 negative group:None

TAO, IgG4 positive group:None

Healthy adults:None

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1.Individuals aged 18-70 years, diagnosed with TAO (according to Bartley's diagnostic criteria), who understand the purpose of this study and agree to cooperate.

Exclusion criteria

Exclusion criteria: 1.Patients who have metabolic diseases (such as diabetes), autoimmune diseases (such as severe myodynamia, multiple sclerosis, ankylosing spondylitis, systemic lupus erythematosus, rheumatoid arthritis, etc.) or other diseases that may affect the immune status (such as hepatitis B, tuberculosis, malignant tumors, etc.) in the past, and who have applied immunosuppressive drugs in the past three months. Pregnant and lactating women.

Design outcomes

Primary

Measure	Time frame
IgG4;	—

Countries

China

Contacts

Public ContactYe Huijing

The Zhongshan Ophthalmic Center,Sun Yat-sen University

yehuijing@qq.com+86 20 87331539

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026